DE60017783D1 - Biomolekularer komplex gebilded aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung - Google Patents

Biomolekularer komplex gebilded aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung

Info

Publication number
DE60017783D1
DE60017783D1 DE60017783T DE60017783T DE60017783D1 DE 60017783 D1 DE60017783 D1 DE 60017783D1 DE 60017783 T DE60017783 T DE 60017783T DE 60017783 T DE60017783 T DE 60017783T DE 60017783 D1 DE60017783 D1 DE 60017783D1
Authority
DE
Germany
Prior art keywords
biomolecular
manufacturing
hyaluronic acid
therapeutic use
complex made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017783T
Other languages
English (en)
Other versions
DE60017783T2 (de
Inventor
Gustaf Jederstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60017783D1 publication Critical patent/DE60017783D1/de
Publication of DE60017783T2 publication Critical patent/DE60017783T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60017783T 1999-11-15 2000-11-15 Biomolekularer komplex,gebildet aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung Expired - Lifetime DE60017783T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904121A SE9904121D0 (sv) 1999-11-15 1999-11-15 Hydrophobe biomolecular structure
SE9904121 1999-11-15
PCT/SE2000/002245 WO2001036656A2 (en) 1999-11-15 2000-11-15 A complex between hyaluronic acid and a biomolecule and its use

Publications (2)

Publication Number Publication Date
DE60017783D1 true DE60017783D1 (de) 2005-03-03
DE60017783T2 DE60017783T2 (de) 2006-01-05

Family

ID=20417718

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017783T Expired - Lifetime DE60017783T2 (de) 1999-11-15 2000-11-15 Biomolekularer komplex,gebildet aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung

Country Status (9)

Country Link
US (3) US6448093B1 (de)
EP (1) EP1231926B1 (de)
AT (1) ATE287720T1 (de)
AU (1) AU1748101A (de)
CA (1) CA2391647C (de)
DE (1) DE60017783T2 (de)
ES (1) ES2236004T3 (de)
SE (1) SE9904121D0 (de)
WO (1) WO2001036656A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CN1309392C (zh) * 2002-02-15 2007-04-11 研究发展基金会 透明质酸介导的腺病毒转导
JP4851185B2 (ja) 2003-05-16 2012-01-11 ジェレックスインターナショナル株式会社 アレルギー症状抑制剤及び空気濾過フィルター
CN103784960A (zh) 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
AU2006289651B2 (en) * 2005-09-07 2012-07-26 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
EP2146750B1 (de) * 2007-05-07 2011-07-13 Jederstrom Pharmaceuticals AB Stabilisierte suspension
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
SE7901565L (sv) 1979-02-21 1980-08-22 Pharmacia Ab Medel for immunisering
DE2907070A1 (de) * 1979-02-23 1980-09-04 Hoechst Ag Heterocyclische spiroverknuepfte amidine und verfahren zu ihrer herstellung
LU85582A1 (fr) * 1983-10-11 1985-06-04 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique,procedes pour leur preparation et compositions pharmaceutiques les contenant
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
SE8804164A0 (sv) 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
DE69227607T2 (de) 1991-07-10 1999-04-15 Takeda Chemical Industries Ltd Arzneimittel auf Basis von Hyaluronsäure
US5614212A (en) * 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5654006A (en) * 1993-02-12 1997-08-05 Mayo Foundation For Medical Education And Research Condensed-phase microparticle composition and method
US6087171A (en) * 1993-12-17 2000-07-11 Spinal Cord Society Method for inducing DNA synthesis in neurons
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
WO1996029998A1 (en) * 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres comprising a biocompatible polysaccharide
KR19990066967A (ko) 1995-10-23 1999-08-16 둘헌티 브리안 비정상적인 망막 혈관형성을 치료하기 위한 유전자 치료법과vegf 안티센스용 dna 운반체로써 사용되는 히알루론산
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
JPH10158196A (ja) * 1996-05-16 1998-06-16 Hisamitsu Pharmaceut Co Inc 核酸安定化用キャリアー
AU726518C (en) * 1996-07-10 2002-01-03 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions suitable for delivery of genes to epithelial cells
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure

Also Published As

Publication number Publication date
US20070275069A9 (en) 2007-11-29
EP1231926B1 (de) 2005-01-26
DE60017783T2 (de) 2006-01-05
US7338931B2 (en) 2008-03-04
WO2001036656A2 (en) 2001-05-25
US6926910B2 (en) 2005-08-09
AU1748101A (en) 2001-05-30
EP1231926A2 (de) 2002-08-21
ES2236004T3 (es) 2005-07-16
US20030096266A1 (en) 2003-05-22
US20050255162A1 (en) 2005-11-17
ATE287720T1 (de) 2005-02-15
CA2391647C (en) 2008-03-11
SE9904121D0 (sv) 1999-11-15
WO2001036656B1 (en) 2002-02-28
US6448093B1 (en) 2002-09-10
CA2391647A1 (en) 2001-05-25
WO2001036656A3 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
DE60017783D1 (de) Biomolekularer komplex gebilded aus hyaluronsäure und einem biomolekül, herstellungsverfahren dafür und deren therapeutische verwendung
EA200200551A1 (ru) Новые содержащие тиотропий порошки для ингаляции
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ATE386030T1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
BR0015544A (pt) Polimorfo estável de cloridrato de n-( 3-etinilfenilamino )-6,7-bis( 2-metoxietóxi)-4-quinazolinamina, métodos de produção, e usos farmacêuticos dos mesmos
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
CY1106774T1 (el) Συνθεσεις φαρμακευτικων μεσων με βαση αλατα του τιοτροπιου και αλατα της σαλμετερολης
DE60008866D1 (de) Heteroaryl diazabicycloalkene, deren herstellung und verwendung
FR2824272B1 (fr) Charge prothetique pour un corps vivant, et procede pour sa production
EA200301040A1 (ru) Способ производства фармацевтической композиции низкой дозы
AU2001293802A1 (en) Substituted cinnamic acid guanidides, method for the production thereof, their use as a medicament, and to medicament containing these compounds
CY1108377T1 (el) Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
SE0100569D0 (sv) New compounds
BR0013316A (pt) Derivados substituìdos de 2-dialquilaminoalquilbifenila, seu processo de fabricação e seu uso.
SE9802206D0 (sv) Novel compounds
ATE367815T1 (de) Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
ZA200308353B (en) Compaction process for manufacture of sodium phenytoin dosage form.
SE0100566D0 (sv) Compounds
HUP0002170A2 (hu) Egy specifikus 5HT2 receptor antagonista alkalmazása alvás közben fellépő apnoe szindróma kezelésére szolgáló gyógyszerkészítmény előállítására
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
ATE301990T1 (de) Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DE50008032D1 (de) Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition